Metastasis Progression Analysis
Metastasis Progression Analysis - Related Videos
08:40
Quantitative Analysis of Cancer Metastasis using an Avian Embryo Model
0 Views •
Cited by 90 •
2011
Using quantitative PCR, we demonstrate how the well-established chick CAM model can be used to quantitatively analyze the metastasis of human tumor cells to distant organs.
07:42
Modelling Brain Metastasis: Standardized Analysis of Metastatic Colonization and Histological Growth Patterns by Stereotactic Intracortical Injection
0 Views •
Cited by 1 •
2026
The stereotactic intracranial injection technique enables precise and localized implantation of tumor cells into the mouse cortex, making it a powerful model for studying metastatic colonization of the brain.
08:28
Experimental Metastasis Assay
0 Views •
Cited by 28 •
2010
This article describes the procedures of an experimental metastasis assay that is used to determine the metastatic potential of human cancer cell lines.
08:49
Models of Bone Metastasis
0 Views •
Cited by 115 •
2012
Animal models are frequently utilized to study cancer metastasis to bone. In this protocol we will describe two common methods of tumor inoculation for bone metastasis studies and briefly describe some of the analyses utilized to monitor and quantify these models.
11:43
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
0 Views •
Cited by 6 •
2016
The ability of metastatic clones to colonize distant sites depends on their proliferation capacity and/or their ability to survive in the host microenvironment without significant proliferation. Here, we present an animal model that allows quantitative visualization of both types of liver colonization by metastatic clones.
FAQs
Treating dissemination as a sequence helps investigators locate where progression may be interrupted. Local invasion, vessel entry, survival in circulation, tissue exit, and colonization represent distinct transitions rather than one uniform event. Comparing these steps can reveal which part of the metastatic course is associated with risk or an opportunity to limit spread.
Histopathology shows tissue-level features, molecular profiling characterizes tumor molecular features, imaging follows disease distribution, and experimental models permit controlled investigation. Using these sources together allows researchers to compare structural, molecular, spatial, and experimentally observed evidence. Their combination supports more comprehensive characterization than relying on a single measurement.
Sequential findings can support biomarker development by linking observed tumor characteristics with metastatic risk. Molecular profiling may identify patterns associated with dissemination, while histopathology and imaging provide complementary evidence about tumor structure and distribution. Such markers can contribute to patient stratification, helping distinguish risk profiles relevant to prognosis and treatment planning.
A practical workflow combines evaluation of tumor tissue, molecular profiling, imaging, and experimental models. Investigators examine the progression sequence, relate findings across local invasion and distant disease, and assess patterns associated with metastatic risk. Integrating these observations produces a broader evidence base for characterizing dissemination than any single analytical approach can provide.
Experimental models provide a controlled setting for examining dissemination-related processes and for evaluating therapies designed to prevent or limit cancer spread. Their findings can be considered alongside histopathology, molecular profiling, and imaging results. This comparison helps researchers assess whether an observed treatment effect or progression pattern is consistent across complementary forms of evidence.
The analysis supports clinical interpretation by characterizing metastatic risk and identifying patterns associated with the development of secondary tumors. Researchers can use these findings for patient stratification, while imaging, tissue examination, and molecular data contribute distinct evidence for assessment. The resulting information helps connect disease progression with prognosis and decisions about treatment planning.